740 related articles for article (PubMed ID: 15288507)
1. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
[TBL] [Abstract][Full Text] [Related]
2. Selective alterations of gene expression in mice induced by MPTP.
Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
4. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
5. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
6. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
Song DD; Shults CW; Sisk A; Rockenstein E; Masliah E
Exp Neurol; 2004 Apr; 186(2):158-72. PubMed ID: 15026254
[TBL] [Abstract][Full Text] [Related]
7. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).
Numis AL; Unger EL; Sheridan DL; Chisnell AC; Andrews AM
Mol Pharmacol; 2004 Sep; 66(3):718-27. PubMed ID: 15322265
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
9. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Shimoji M; Zhang L; Mandir AS; Dawson VL; Dawson TM
Brain Res Mol Brain Res; 2005 Mar; 134(1):103-8. PubMed ID: 15790534
[TBL] [Abstract][Full Text] [Related]
10. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
[TBL] [Abstract][Full Text] [Related]
11. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
12. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
14. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice.
Selley ML
Brain Res; 2005 Mar; 1037(1-2):1-6. PubMed ID: 15777746
[TBL] [Abstract][Full Text] [Related]
16. Neurotoxicity in murine striatal dopaminergic pathways following long-term application of low doses of permethrin and MPTP.
Kou J; Bloomquist JR
Toxicol Lett; 2007 Jul; 171(3):154-61. PubMed ID: 17597311
[TBL] [Abstract][Full Text] [Related]
17. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
18. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Jourdain S; Morissette M; Morin N; Di Paolo T
J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
20. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
Rojo AI; Montero C; Salazar M; Close RM; Fernández-Ruiz J; Sánchez-González MA; de Sagarra MR; Jackson-Lewis V; Cavada C; Cuadrado A
Eur J Neurosci; 2006 Oct; 24(7):1874-84. PubMed ID: 17067291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
